Previous 10 | Next 10 |
2023-06-15 09:32:37 ET Markets reacted with some uncertainty to Wednesday's decision from the Federal Reserve to leave interest rates unchanged. Despite the pause, the Fed signaled further potential rate hikes, and that left some investors worrying whether the central bank could exacerbate ...
2023-06-15 08:55:00 ET U.S. stock index futures on Thursday pointed to a lower open, with the Federal Reserve still very much the topic of conversation. The major averages had ended mixed the day before after the central bank held interest rates steady for the first time after ten conse...
2023-06-15 08:24:35 ET Mersana Therapeutics ( MRSN ) -67% on FDA partial hold on trials for lead asset. Bone Biologics Corporation ( BBLG ) -53% on offering prices of $5M . Gambling.com Group Limited ( GAMB ) -15% launches secondary offering of 4....
2023-06-15 07:51:04 ET Mersana Therapeutics ( NASDAQ: MRSN ) lost ~60% pre-market Thursday after announcing that the FDA issued a partial clinical hold halting the enrollment in its UP-NEXT and UPGRADE-A trials for lead asset UpRi in platinum-sensitive ovarian cancer. The ...
CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
2023-06-13 06:00:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In order for a stock to provide 200% returns it needs to at least triple in price. That’s the kind of shares we’ll be discussing below. The positive news here is that all of the...
2023-06-12 17:14:04 ET Gainers: ARS Pharmaceuticals ( NASDAQ: SPRY ) +5% . Mersana Therapeutics ( MRSN ) +4% . Frontier Group ( ULCC ) +2% . Sterling Infrastructure ( STRL ) +2% . Stitch Fix ( SFIX ) +2% . Losers:...
2023-05-09 13:45:17 ET Mersana Therapeutics, Inc. (MRSN) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Jason Fredette – Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas – President and...
2023-05-09 07:20:46 ET Mersana Therapeutics press release ( NASDAQ: MRSN ): Q1 GAAP EPS of -$0.52 misses by $0.09 . Revenue of $7.8M (+284.2% Y/Y) misses by $10.49M . Net cash used in operating activities for the first quarter of 2023 was $29.0 million. Cas...
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023 Advanced enrollment in Phase 3 UP-NEXT clinical trial of UpRi and Phase 1 clinical trial of XMT-1660 Plan to report topline data from ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...